Aaron D Trowbridge, Ciaran P Seath, Frances P Rodriguez-Rivera, Beryl X Li, Barbara E Dul, Adam G Schwaid, Benito F Buksh, Jacob B Geri, James V Oakley, Olugbeminiyi O Fadeyi, Rob C Oslund, Keun Ah Ryu, Cory White, Tamara Reyes-Robles, Paul Tawa, Dann L Parker, David W C MacMillan
Over half of new therapeutic approaches fail in clinical trials due to a lack of target validation. As such, the development of new methods to improve and accelerate the identification of cellular targets, broadly known as target ID, remains a fundamental goal in drug discovery. While advances in sequencing and mass spectrometry technologies have revolutionized drug target ID in recent decades, the corresponding chemical-based approaches have not changed in over 50 y. Consigned to outdated stoichiometric activation modes, modern target ID campaigns are regularly confounded by poor signal-to-noise resulting from limited receptor occupancy and low crosslinking yields, especially when targeting low abundance membrane proteins or multiple protein target engagement...
August 23, 2022: Proceedings of the National Academy of Sciences of the United States of America